Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Visit
VJOncology is excited to present the latest data and developments in the HER2-low breast cancer field, with comments from experts…
The U.S. Food and Drug Administration (FDA) have approved tremelimumab in combination with durvalumab and platinum-based chemotherapy for metastatic non-small…
The U.S. Food and Drug Administration (FDA) has granted priority review for elacestrant, a selective estrogen receptor degrader (SERD), based…
A report published in JAMA Oncology suggests that cancer patients with baseline immunosuppression and COVID-19 experience worse outcomes and an…
VJOncology are excited to highlight the latest in immuno-oncology from the 37th Annual Meeting of the Society for Immunotherapy in…
Over 75% of patients with ovarian cancer are diagnosed at an advanced stage, as early-stage disease is usually asymptomatic.1,2 The…
Antibody-drug conjugates (ADCs) are an emerging class of anticancer drugs consisting of a monoclonal antibody linked to a cytotoxic chemotherapy…
Research presented at the European Society of Medical Oncology (ESMO) Congress 2022 has uncovered a non-mutagenic mechanism by which air…